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Abstract
Background: The existing information on oral rehabilitations with dental implants in VIH-positive patients is 
scarce and of poor quality. Moreover, no long-term follow-up studies are available. Hence, the aims of this study 
were to describe the long-term survival and success rates of dental implants in a group of HIV-positive patients 
and to identify the most common postoperative complications, including peri-implant diseases. 
Material and Methods: A retrospective case series of HIV-positive subjects treated with dental implants at the 
School of Dentistry of the University of Barcelona (Spain) was studied. Several clinical parameters were regis-
tered, including CD4 cell count, viral load and surgical complications. Additionally, the patients were assessed 
for implant survival and success rates and for the prevalence of peri-implant diseases. A descriptive statistical 
analysis of the data was performed. 
Results: Nine participants (57 implants) were included. The patients’ median age was 42 years (IQR=13.5 years). 
The implant survival and success rates were 98.3% and 68.4%, respectively, with a mean follow-up of 77.5 months 
(SD=16.1 months). The patient-based prevalence of peri-implant mucositis and peri-implantitis were 22.2% and 
44.4% respectively at the last appointment. Patients that attended regular periodontal maintenance visits had sig-
nificantly less mean bone loss than non-compliant patients (1.3 mm and 3.9 mm respectively).
Conclusions: Oral rehabilitation with dental implants in HIV-positive patients seems to provide satisfactory re-
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sults. In order to reduce the considerably high prevalence of peri-implant diseases, strict maintenance programmes 
must be implemented.
Key words: HIV infection, dental implants, oral implantology, complications, peri-implantitis, peri-implant dis-
eases.
Introduction
Acquired immune deficiency syndrome (AIDS) is a 
condition caused by the human immunodeficiency vi-
rus (HIV). In 2012 it affected nearly 30 million people 
worldwide (1). Patients suffering from AIDS experience 
an immune depression, caused by HIV infection, which 
reduces the host’s resistance to pathogens. An HIV 
infected patient is seropositive but will only develop 
AIDS symptoms when the CD4 T-helper lymphocyte 
count (CD4) is less than 200 cells/mm (2). Oral mani-
festations of AIDS include oral candidiasis, hairy leu-
koplakia, Kaposi’s sarcoma, HIV-associated gingivitis 
and periodontitis, atypical ulcerations and herpetic in-
fections (3).
The introduction of highly active antiretroviral therapy 
(HAART) in 1996 has reduced HIV-related morbid-
ity and mortality significantly in areas with access to 
antiretrovirals (2), converting this disease into a chronic 
condition. HAART includes a combination of antiret-
roviral medications, such as nucleoside reverse tran-
scriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibi-
tors (PIs), entry inhibitors and integrase inhibitors (4). 
However, these drugs also have some adverse effects, 
including diarrhea, anaemia, dyslipidaemia, pancreati-
tis, hepatotoxicity, hyposalivation and bone metabolism 
disorders like osteopenia, osteonecrosis and osteoporo-
sis (4,5). Nevertheless, these effective treatments can 
keep patients asymptomatic for a long period of time. 
Accordingly, demands for functional and aesthetic den-
tal treatments have increased in recent years. In this 
context, oral rehabilitation with dental implants can be 
a good alternative to traditional removable prostheses. 
Although no long-term longitudinal studies have been 
published on this subject, several papers have suggested 
that immunologically stable patients might be treated 
successfully with implant-prosthetic rehabilitation 
(6-13). On the other hand, some studies have shown that 
when the CD4 count is <200 cells/3, the risk of postop-
erative complications is high (14).
The aims of this study were to describe the long-term 
survival and success rates of dental implants in a group 
of HIV-positive patients and to quantify their most 
common postoperative complications, including peri-
implant diseases.
Material and Methods
A retrospective case series of HIV-positive patients 
consecutively treated with dental implants between July 
2004 and May 2008 in the Oral Surgery and Implantol-
ogy Unit of the School of Dentistry of the University of 
Barcelona was studied.
The study design followed the STROBE guidelines for 
cohort studies (15). The protocol complied with the Hel-
sinki declaration guidelines and was approved by the 
Ethical Committee for Clinical Research (CEIC) of the 
Dental Hospital of the University of Barcelona.
The patients were given full information about the sur-
gical procedures and treatment alternatives and duly 
signed informed consent forms. Preoperative analysis 
included complete medical histories and clinical and ra-
diographic examinations (with panoramic radiographs 
and/or computed tomographic scans).
At the time of implant surgery, all patients presented an 
American Society of Anesthetists (ASA) health status 
score of no higher than 3. Patients with active periodon-
tal disease had been treated previously according to the 
American Academy of Periodontology guidelines (16). 
Patients with incomplete clinical records were excluded 
from the analysis.
All the participants were recalled for a follow-up visit 
in 2014, which included periodontal and peri-implant 
clinical and radiological examinations, in order to as-
sess their implant survival and success rates, measured 
according to the criteria of Albrektsson et al. (17).
- Surgical Procedure
Preoperative consultation with the infectious diseases 
specialist was required in all cases. Recent blood tests, 
dating from less than 2 months previously – including 
basic haemostasis profile, blood biochemistry, haemat-
ic biometry, lymphocyte sub-type counts (CD4, CD8, 
CD4:CD8 ratio, NK) and viral load – were mandatory 
before the surgical procedure.
Final-year postgraduates on the 3-year Master in Oral 
Surgery and Implantology degree course placed the im-
plants under local anaesthesia, generally a 4% solution 
of articaine with 1:100.000 epinephrine, with or without 
simultaneous (multimodal) intravenous conscious seda-
tion with midazolam 2 mg; propofol 0.3-0.5 mg/kg/h 
and remifentanil 0.025-0.05 mcg/kg/min. One hour 
before the surgical procedure, the patients received 2g 
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of amoxicillin. A midcrestal incision was made and 
full-thickness flaps were raised to expose the alveolar 
ridge. The implant sites were prepared using drills of 
increasing diameter under constant irrigation with ster-
ile saline solution, following the manufacturers’ rec-
ommendations. Functional and aesthetic requirements 
were taken into account in determining the mesiodistal 
and buccolingual inclination of the implants and the 
need for guided bone regeneration (GBR) procedures. 
The flaps were usually repositioned with 4-0 Supramid 
sutures (Supramid®; Aragó, Barcelona, Spain). The su-
ture was removed 7 to 15 days after surgery. 
After the operation, an antibiotic (usually amoxicil-
lin 750 mg every 8 hours for 7 days), a nonsteroidal 
anti-inflammatory drug (usually sodium diclofenac 
50 mg every 8 hours for 4-5 days), an analgesic (usu-
ally paracetamol 1 g every 8 hours for 3-4 days), and 
a mouthrinse (0.12% chlorhexidine digluconate 15 ml 
every 12 hours for 15 days) were prescribed.
The postoperative instructions and prescribed drugs 
were explained verbally and on a sheet of paper that was 
given to the patient. The patients’ compliance was not 
specifically assessed.
The patients were recalled for a periodontal and peri-
implant maintenance visit at least once a year. Every 
follow-up appointment consisted of oral hygiene in-
structions, prosthesis maintenance and a complete peri-
odontal examination which checked the probing pocket 
depth (PPD), the modified plaque and gingival index ac-
cording to Mombelli et al. (18) (mPI and mGI), bleeding 
on probing (BoP) and suppuration. 
During the latest follow-up visit, periapical digital radi-
ographs using long-cone parallel technique X-rays were 
obtained in order to measure the bone levels (BL). A 
single researcher (OCF) assessed the mesial and distal 
aspects of each implant and recorded the highest value. 
All the radiographs were examined twice, 1 week apart, 
to verify intra-examiner reproducibility. The intraclass 
correlation coefficient (ICC) was 0.908 (95% CI: 0.867-
0.941; p<0.001), indicating nearly perfect agreement. 
Each implant was assessed for the presence of peri-im-
plant diseases, applying the following diagnostic crite-
ria suggested by Koldsland et al. (19):
- Health: BL < 2 mm with mGI = 0
- Inflammation: any BL with mGI ≥ 1
* Peri-implant mucositis: BL < 2 mm with mGI ≥ 1
* Peri-implantitis: BL ≥ 2 mm with mGI ≥ 1 or suppuration.
For a patient to be considered healthy, all his or her im-
plants had to be classified as healthy. If any of the im-
plants was classified into the mucositis or peri-implan-
titis groups, the patient was considered not healthy. The 
patients were classified into the group of their worst im-
plant. Specific treatment for peri-implant diseases was 
given if needed.
Compliance with periodontal maintenance was defined 
as attendance at more than two-thirds of the scheduled 
visits.
- Data sampling
All the clinical records were examined by the same re-
searcher (OCF), who collected the following data: age; 
gender; smoking habit (non-smoker, 1 to 10 cigarettes/
day, or more than 10 cigarettes/day); drug habits; year of 
HIV infection diagnosis; HIV transmission route (sex-
ual, parenteral or transfusion); CD4 lymphocyte count; 
viral load; antiretroviral therapy; periodontal disease 
(healthy or periodontally compromised); quality and 
quantity of available alveolar bone using the most wide-
ly accepted classification according to Ribeiro-Rotta 
et al. (20); implant manufacturer; location (maxilla or 
mandible); position (anterior or posterior); primary sta-
bility (considered when insertion torque was over 15 
N·cm2); intra and/or postoperative complications; time 
from implant placement to prosthetic loading (immedi-
ate: within the first week; early: between 1 week and 3 
months in the mandible and 1 week and 4 months in the 
maxilla; conventional, at least 3 months in the mandible 
and 4 months in the maxilla); type of prosthetic restora-
tion; date of the most recent follow-up; and peri-implant 
parameters (BoP, PPD, mGI, BL and suppuration).
- Statistical analysis
The statistical analysis was carried out with the Sta-
tistical Package for the Social Sciences (SPSS version 
22.0; IBM Corp.; Armonk, NY, USA). The normal-
ity of the scale variables (patient age, CD4 cell count, 
PPD, time elapsed from implant placement to prosthetic 
loading and follow-up period) was explored using the 
Shapiro-Wilks test. Where normality was rejected, the 
interquartile range (IQR) and median were calculated. 
Where distribution was compatible with normality, the 
mean and standard deviation (SD) were used. The level 
of significance was set at p<0.05. Ninety-five percent 
confidence intervals (95% CI) were calculated for all 
prevalences.
Results
Fifty-seven dental implants were placed in 9 patients 
who met the inclusion criteria. 
The median age of the patients was 42 years (IQR=13.5 
years). There were 5 males (55.6%) and 4 females 
(44.4%). Six patients (66.7%) were smokers, 2 (22.2%) 
were regular cannabis smokers and 4 (44.4%) had a his-
tory of intravenous drug dependence. The median CD4 
cell count was 436.0 cells/mm3 (IQR=606.5 cells/mm3) 
and viral load values were undetectable (<50 copies/
mL) in 8 patients (88.9%). Table 1 shows the main fea-
tures of the sample. 
All the implants were inserted at least 4 months after 
tooth extraction. GBR procedures were required in 
cases 1 (simultaneously) and 3 (prior to implant place-
ment). Neither intra- nor early post-operative compli-
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cations were reported. All the implants were conven-
tionally loaded with the exception of case 4 (immediate 
loading).
The implant survival and success rates were 98.3% (one 
implant failed in case 3 due to peri-implantitis) and 
68.4% respectively, with a mean follow-up period of 
77.5 months (SD=16.1 months). Table 2 describes some 
of the HIV-patients’ clinical features and treatment out-
comes.
Six implants (2 patients) presented mucositis and 26 im-
plants (4 patients) were diagnosed with peri-implantitis. 
The patient and implant-based prevalences of these 
complications were 22.2% (95%CI: 6.3% to 54.7%) 
and 10.5% (95%CI: 4.9% to 21.1%) for mucositis and 
44.4% (95%CI: 18.9% to 73.3%) and 45.6% (95%CI: 
33.4% to 58.4%) for peri-implantitis. Table 3 summa-
rizes the peri-implant examination results at the most 
recent follow-up appointment. Only 1 of the 5 patients 
that complied with the periodontal/peri-implant main-
tenance visits had peri-implantitis, whereas all the non-
compliant patients were classified as not healthy (3 had 
peri-implantitis and 1 had mucositis) (Tables 1-3).
Discussion
The present study, conducted after 5 to 9 years of fol-
low-up, indicates that oral rehabilitation with dental 
implants is a valid treatment option for HIV-positive 
patients.
A commonly accepted surgical principle is that immu-
nocompromised patients have an increased risk of post-
operative complications due to their inability to gen-
erate a controlled, appropriate and sustained immune 
response (21). However, even though literature on this 
subject is scarce, all the studies published reveal that 
implant placement in immunologically stable HIV-pos-
itive patients does not increase the risk of developing 
postoperative complications such as infection or wound-
healing impairment (6-12). Although Patton et al. (14) 
found significantly higher rates of postoperative com-
plications following tooth extractions when pronounced 
immunosuppression (CD4 cell count <200 cells/mm3) 
and severe neutropenia (neutrophilic leukocytes <500 
cells/3) were recorded, most authors have found no as-
sociation between HIV infection and the occurrence of 
postoperative problems with other minor oral surgery 
 
Case Age (years) Gender* 
Year  
of 
infection 
Transmission Antiretroviral therapy† 
CD4 
count 
(cells/mL) 
Viral load 
(copies/mL)‡ 
Smoking 
(cigarettes/day) 
Drug    
habits§  
Periodontal 
disease 
1 65 F 2005 Sexual 
Emtricitabine 
Tenofovir 
Efavirenz 
448 
28% Undetectable No No Advanced 
2 78 M 2003 Transfusion 
Lopinavir/Rit
onavir 
Emtricitabine 
Tenofovir 
242 
14% Undetectable No No Advanced 
3 43 F 1996 Parenteral 
Abacavir 
Lamivudine 
Zidovudine 
436 
17.1% Undetectable 20 
Former 
IDU 
Cannabis 
Advanced 
4 40 F 2002 Sexual No medication 
875 
44.4% 59 10 No Moderate 
5 34 F 1998 Parenteral 
Abacavir 
Lamivudine 
Zidovudine 
888 
43.8% Undetectable 5 
Former 
IDU Moderate 
6 42 M 1990 Parenteral 
Lopinavir/Rit
onavir 
Tenofovir 
Lamivudine 
315 
13% Undetectable 20 
Former 
IDU 
Cannabis 
Advanced 
7 43 M 1997 Sexual 
Lamivudine 
Zidovudine 
Nevirapine 
259 
15% Undetectable No No No 
8 41 M 1987 Parenteral 
Lamivudine 
Stavudine 
Ritonavir 
1115 
33% Undetectable 30 
Former 
IDU No 
9 41 M 1999 Sexual 
Abacavir 
Lamivudine 
Zidovudine 
912 
26% Undetectable 20 No Advanced 
Table 1. Main demographic characteristics of the patients.
* M: Male; F: Female
† Abacavir 300 mg; Efavirenz 600 mg; Emtricitabine 200 mg; Lamivudine 150 mg; Lopinavir/Ritonavir 200/50 mg; 
Neviparine 200 mg; Ritonavir 100 mg; Stavudine 30 mg; Tenofovir 163 mg; Zidovudine 250 mg
‡ Undetectable: <50 copies/mL
§ IDU: Intravenous Drug User.
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procedures (21-23). In the present case series, no early 
postoperative complications were reported. However, 
the degree of immunosuppression seems to be an im-
portant variable and further research is needed to cor-
roborate these findings. 
The major limitations of the present study are its retro-
spective nature and the fact that several non-calibrated 
dentists conducted the periodontal/peri-implant main-
tenance visits. In order to limit the effect of these bi-
ases, a single researcher made the final assessment of 
Case Bone quality* 
Bone 
quantity
* 
Implant 
manufacturer 
Location 
(n) Position 
Prosthetic 
restoration† 
Follow-up 
after 
loading 
(months) 
Periodontal 
compliance Implant status 
1 IV II 
B 
B Nobel Biocare 
Maxilla (6) 
Mandible 
(4) 
Anterior + 
Posterior 
FFA 
HP 54 Yes 
Healthy: 8 implants 
Mucositis: 2 implants 
Peri-implantitis: None 
Failures: None 
2 III B Defcon Mandible (6) 
Anterior + 
Posterior HP 79 Yes 
Healthy: 2 implants 
Mucositis: 1 implants 
Peri-implantitis: 3 
implants 
Failures: None 
3 III II 
C 
B Astra 
Maxilla (4) 
Mandible 
(3) 
Anterior 
Posterior 
OD 
SC (1) FPP 
(1) 
61 No 
Healthy: None 
Mucositis: 1 implant 
Peri-implantitis: 5 
implants 
Failures: 1 implant 
4 I B Nobel Biocare Mandible (6) 
Anterior + 
Posterior HP 68 No 
Healthy: None 
Mucositis: None 
Peri-implantitis: 6 
implants 
Failures: None 
5 III I 
B 
A Defcon 
Maxilla (3) 
Mandible 
(4) 
Posterior 
Posterior 
SC (1) FPP 
(1) 
FPP (2) 
85 Yes 
Healthy: 7 implants 
Mucositis: None 
Peri-implantitis: None 
Failures: None 
6 III II 
C 
C Defcon 
Maxilla (5) 
Mandible 
(6) 
Anterior + 
Posterior 
OD 
OD 91 No 
Healthy: None 
Mucositis: None 
Peri-implantitis: 11 
implants 
Failures: None 
7 II A Defcon Mandible (2) Posterior SC 103 No 
Healthy: None 
Mucositis: 2 implants 
Peri-implantitis: None 
Failures: None 
8 I B Straumann Mandible (2) Posterior SC 101 Yes 
Healthy: 2 implants 
Mucositis: None 
Peri-implantitis: None 
Failures: None 
Table 2. Clinical features and treatment outcomes.
† SC: Single Crown; FPP: Fixed Partial Prosthesis; OD: Overdenture; HP: Hybrid Metal-Resin Prosthesis; FFA: Fixed Full-arch.
* According to Lekholm & Zarb’s classification.
 
 PPD BL BoP mPI mGI 
Compliant patients*  2.8 ± 1.0 mm 1.3 ± 0.6 mm 19.4% 0.6 ± 0.9 0.4 ± 0.8 
Non-compliant patients 5.2 ± 2.0 mm 3.9 ± 1.9 mm 66.6% 2.0 ± 0.9 2.5 ± 0.5 
Significance p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 
Total 3.8 ± 2.0 mm 2.5 ± 1.9 mm 40.5% 1.2 ± 1.1 1.3 ± 1.3 
Table 3. Peri-implant parameters at the most recent follow-up appointment.
*Regular periodontal and peri-implant maintenance visits. PPD: Probing pocket  depth. BL: bone levels. BoP: bleeding on probing. 
mPI: modified plaque index. mGI: modified gingival index.
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all the cases, enabling objective data to be gathered on 
the main outcome variables (success and survival rates 
and peri-implant disease parameters). The low number 
of patients included in this study can also be considered 
a limitation. However, taking into account the lack of 
large-sample studies published in the literature on this 
subject and the long-term data this study provides, we 
think that the information reported in this paper will 
prove extremely interesting and useful to clinicians.
Baron et al. (6) suggested that a temporary reduction in 
CD4 cell counts after implant placement may happen 
due to an inflammatory process at the surgery site. This 
was not the case here, or in most of the studies cited 
(7-12), since no alterations in CD4 cell count or in other 
analytical parameters were observed during the follow-
up period.
Although several authors claim that conventional pro-
tocols should be maintained in cases of immunological 
stability (6-12), most clinicians systematically prescribe 
both preoperative and postoperative antibiotics when in-
vasive dental procedures are performed in HIV-positive 
patients (24). Hence, most administer systemic antibiot-
ics (usually amoxicillin) during the first 5 to 7 days after 
implant placement (6-11). Further research on this topic 
is needed to confirm which regime is the most suitable 
for immunocompromised patients. 
Dental implants are considered a safe and predict-
able treatment method with high rates of both surviv-
al and success after 5 and 10 years (25,26). Although 
the present findings confirm high long-term implant 
survival rates (98%), only 68% fulfilled the Albrekts-
son et al. (17) success criteria (27-29). This might be 
associated with the features of the sample, since there 
was a high rate of patients who smoked and also had 
a previous history of periodontitis, both of which are 
strong risk indicators for peri-implant pathology (30). 
Furthermore, several patients failed to attend regular 
periodontal maintenance visits. Indeed, an examination 
of this variable (Table 2) shows that the 4 non-compli-
ant patients were diagnosed with peri-implantitis (in 3 
cases) or with mucositis (1 patient), whereas the remain-
ing 5 patients, who attended the follow-up visits, had 
considerably less peri-implant disease (3 were healthy, 
1 had mucositis and 1 was diagnosed with peri-implan-
titis). Moreover, significantly better results for all the 
peri-implant parameters were reported in the compliant 
patients (Table 3) (31). Obviously, HIV infection might 
also play an important role in these complications. In 
fact, several periodontal lesions have been described 
in HIV positive patients (3), including linear gingival 
erythema and necrotizing periodontal diseases, as well 
as possible exacerbation of pre-existing periodontal dis-
eases. All these factors highlight the need to implement 
strict maintenance protocols to prevent the onset and 
progression of peri-implant diseases in these patients.
In conclusion, oral rehabilitation with dental implants 
in HIV-positive patients with CD4+ cell counts of >200/
µL and undetectable viral loads seems to provide satis-
factory results. In order to reduce the very high preva-
lence of peri-implant diseases in HIV positive patients, 
strict periodontal maintenance programmes must be 
implemented.
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